Volume 3, Issue 7, Page 12 (July 2007)
10 of 22
PREVIEW
FULL TEXT
FULL-TEXT PDF (99 KB)
CITATION ALERT
CITED BY
RELATED ARTICLES
EXPORT CITATION
EMAIL TO A COLLEAGUE
RIGHTS/PERMISSIONS
NEED REPRINTS?
BOOKMARK ARTICLE
A transdermal formulation of the cholinesterase inhibitor rivastigmine has been approved by the Food and Drug Administration for mild to moderate dementia in patients with Alzheimer's disease and in those with Parkinson's disease.
PII: S1553-3212(07)70216-9
doi:10.1016/S1553-3212(07)70216-9
© 2007 Elsevier Inc. All rights reserved.
Copyright © 2012 Elsevier Inc. All rights reserved. | Privacy Policy | Terms & Conditions | Feedback | About Us | Help | Contact Us | The content on this site is intended for health professionals.
PREVIEW